GBS Venture Partners
Allergan to acquire Australia's VC-backed Elastagen
Allergan, a US-listed pharmaceutical company and the owner of Botox cosmetic injectable products, has agreed to acquire Elastagen, an Australian skin treatment developer backed by a number of VCs, in a deal worth up to $260 million.
Novartis buys VC-backed Australian drug developer Spinifex
Australian life sciences specialists Brandon Capital Partners and GBS Ventures will exit local drug developer Spinifex Pharmaceuticals after Novartis agreed to buy the business for $200 million in cash plus unspecified earn-outs.
Australia VC: Policy permutations
Plans to reinstate tax breaks for Australian start-ups that issue share options to staff rather than pay sizeable salaries has cheered VC investors. They are generally positive about the government role in fostering innovation
Australia VC: New faces
A new generation of VC firms is emerging in Australia, despite little appetite for the asset class from domestic LPs. Success hinges on leveraging Silicon Valley networks and targeting particular market niches
Australian venture capitalists face commercialization obstacles
Entrepreneurs are brimming with ideas but Australia’s venture capital firms don’t have the capital to convert innovation into products. Government support has so far been piecemeal
Australian VC firms back Spinifex Pharmaceuticals
GBS Venture Partners, Brandon Capital Partners, Uniseed Management and UniQuest have participated in the Series B round of financing for Spinifex Pharmaceuticals. The Australian drug development company raised a total of $19 million, $6.5 million more...
MIVCC sees both side of Oz VC
The Melbourne International Venture Capital Conference (MIVCC) held on March 8 as a joint venture between AVCJ and the Victoria government, brought together venture firms from across Australia, domestic LPs and government representatives to explore the...
Australia’s VC industry
Small relative to the buyout community, and in its nascent stages compared to powerhouses like the US, Australia’s venture capital industry is quietly growing, producing returns that LPs should be taking note of. In advance of the 2011 Melbourne International...
GBS Venture, CM Capital invest in Pathway Therapeutics
New Zealand pharmaceuticals developer Pathway Therapeutics has sparked a private equity round of Series A Funding following its announcement that it is near to marketing a new breast cancer drug.